IPS results suggested that the patients with low-risk score showed a promising response to anti-CTLA-4, anti-PD-1 and anti CTLA-4/anti-PD-1, illustrating a better benefit for immunotherapy of STAD patients in the low-risk group (Figures 7F, G). Here, CTLA4 is linked to gastric adenocarcinoma.